(firstQuint)Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects.

 This is a Phase 3, repeat dose, open-label, safety study in Epilepsy subjects who have frequent breakthrough seizures or Acute Repetitive Seizures (ARS).

 NRL-1 will be administered as needed to treat bouts of those seizures over a 12-month period of time.

 Doses will be defined as 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.

 A diary will be used to record the seizure and NRL-1 administration.

.

 Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects@highlight

This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1